Three doses of Pfizer’s anti-Covid vaccine effective in children under 5

mild side effects

According to the new data, 1,678 children received the third dose at least two months after the second dose, at a time when the Omicron variant was dominant.

Analysis of a subset of participants showed that antibody levels were similar to those seen in 16 to 25-year-olds who received two doses. No new adverse events were identified, and most side effects were mild or moderate.

“According to Pfizer’s press release, all three doses of its COVID vaccine appear to be very safe and highly effective in preventing not only serious illness, hospitalization, and death from COVID, but also symptomatic COVID-19 at a time when That’s when Omicron was the major version, Celine Gounder, chief public health editor at Kaiser Health News, told AFP.

“However, we do know that protection against SARS-CoV-2 infection and mild symptomatic disease diminishes over time,” said Gounder, an infectious disease specialist and epidemiologist.

“Pfizer reports follow-up data up to seven days after the third dose of vaccine. It is too early to say how the three doses will work after several months or a year.”

“I wish the two-dose vaccine had worked for Pfizer-BioNtech. It didn’t. But the three-dose series has given these very young children the protection we want,” said department’s Jeremy Faust. Health told AFP the emergency medical at Brigham and Women’s Hospital in Boston.

Serious COVID illness is very rare in people under the age of five. The United States has recorded 477 deaths in this age group, which is 0.1% of all deaths.